The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity in patients with relapsed/refractory TCL in a phase 2 trial. The mTOR pathway was activated i...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Blood
Κύριοι συγγραφείς: Witzig, Thomas E., Reeder, Craig, Han, Jing Jing, LaPlant, Betsy, Stenson, Mary, Tun, Han W., Macon, William, Ansell, Stephen M., Habermann, Thomas M., Inwards, David J., Micallef, Ivana N., Johnston, Patrick B., Porrata, Luis F., Colgan, Joseph P., Markovic, Svetomir, Nowakowski, Grzegorz S., Gupta, Mamta
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2015
Θέματα:
Clinical Trials and Observations
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4504947/
https://ncbi.nlm.nih.gov/pubmed/25921059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-629543
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια